search
Back to results

Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments (PBSAAF)

Primary Purpose

Acute Anal Fissure

Status
Completed
Phase
Phase 4
Locations
Italy
Study Type
Interventional
Intervention
Centella
Proctocella
Flavonil® cps
Flavonil® Cream
Rectalgan Mousse
Sponsored by
University of Roma La Sapienza
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Anal Fissure focused on measuring Anal Fissure, local therapy, pain, defecation, bleeding

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects With Acute Anal Fissure
  • Collaborative patients able to understand and want;

Exclusion Criteria:

  • Pregnancy

Sites / Locations

  • Department of General Surgery "Paride Stefanini", University of Rome "La Sapienza"

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

AAF treated with Centella® Complex

AAF treated with Proctocella® cream

AAF treated with Flavonil® cps

AAF treated with Flavonil® Cream

AAF treated with Rectalgan Mousse

Arm Description

Centella® Complex 1 cps 60 mg per os

Proctocella® Complex cream to be applied in anal area and anal canal

Flavonil® 1 cps 300 mg per os

Flavonil® Cream Cream to be applied in anal region and anal canal

Rectalgan Mousse cleansing cleanser for anal and perineal region

Outcomes

Primary Outcome Measures

time for the disappearance of pain
time for the disappearance of pain in course of treatment

Secondary Outcome Measures

time for the disappearance of bleeding
time for the disappearance of bleeding in course of treatment

Full Information

First Posted
November 22, 2017
Last Updated
July 11, 2018
Sponsor
University of Roma La Sapienza
search

1. Study Identification

Unique Protocol Identification Number
NCT03355846
Brief Title
Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments
Acronym
PBSAAF
Official Title
Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
May 1, 2018 (Actual)
Primary Completion Date
May 1, 2018 (Actual)
Study Completion Date
May 1, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Roma La Sapienza

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Starting from the observation that acute anal fissure (AAF) in 6-8 weeks can heal spontaneously and that some of the commonly used commercial products in clinical practice would seem to be useful, the rationale of the comparative study is to try to identify, in compliance with the protocol of Helsinki (2013), the most effective short-term treatment for the disappearance of pain in defecation and cessation of bleeding, shortening the duration of the healing process and favoring the patient's rapid return to his / her activity, respect for patient safety.
Detailed Description
Starting from the observation that anal fissure in 6-8 weeks can heal spontaneously and that some of the commonly used commercial products in clinical practice would seem to be useful, the rationale of the comparative study is to try to identify, in compliance with the protocol of Helsinki (2013), the most effective short-term treatment for the disappearance of pain in defecation and cessation of bleeding, shortening the duration of the healing process and favoring the patient's rapid return to his / her activity, respect for patient safety. The comparative study will be conducted by comparing the following products: Centella® Complex 1 cps 60 mg per os after meals twice a day for 15 days; Proctocella® Complex cream to be applied in anal area and anal canal after hygiene treatment for 4 weeks; Flavonil® 1 cps 300 mg per os after meals twice a day for 15 days; Flavonil® Cream Cream to be applied in anal region and anal canal after hygiene treatment for 4 weeks; Rectalgan Mousse cleansing cleanser for anal and perineal region for 4 weeks. Our approach attempts to blend, based on the evidence of the most recent scientific literature, the experience of decades of colonproctologic clinical practice that has a predominantly surgical approach, with the clinical evidence of the Science of Nutrition which has a conservative vision in the treatment of ailments and constipation, a predisposing factor in the pathogenesis of anal fissure, in order to obtain healing without surgery. The control group will receive the traditional basic treatment consisting in the application of lubricated anal dilators of increasing gauge according to predetermined pattern, hygiene and diet. The two groups with which they will be compared for the results will receive, in addition to the foregoing (for controls), or Flavonoids (ProtFlav) or Asian Centella Extract (ProtCent), in the form of local mouth and cream tablets to be applied at the perianal level and possibly in the anal canal with gloved finger, containing the same active principles also administered by mouth.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Anal Fissure
Keywords
Anal Fissure, local therapy, pain, defecation, bleeding

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
99 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AAF treated with Centella® Complex
Arm Type
Experimental
Arm Description
Centella® Complex 1 cps 60 mg per os
Arm Title
AAF treated with Proctocella® cream
Arm Type
Experimental
Arm Description
Proctocella® Complex cream to be applied in anal area and anal canal
Arm Title
AAF treated with Flavonil® cps
Arm Type
Experimental
Arm Description
Flavonil® 1 cps 300 mg per os
Arm Title
AAF treated with Flavonil® Cream
Arm Type
Experimental
Arm Description
Flavonil® Cream Cream to be applied in anal region and anal canal
Arm Title
AAF treated with Rectalgan Mousse
Arm Type
Experimental
Arm Description
Rectalgan Mousse cleansing cleanser for anal and perineal region
Intervention Type
Drug
Intervention Name(s)
Centella
Intervention Description
after meals twice a day for 15 days
Intervention Type
Drug
Intervention Name(s)
Proctocella
Intervention Description
after hygiene treatment for 4 weeks;
Intervention Type
Drug
Intervention Name(s)
Flavonil® cps
Intervention Description
after meals twice a day for 15 days
Intervention Type
Drug
Intervention Name(s)
Flavonil® Cream
Intervention Description
treatment for 4 weeks; .
Intervention Type
Drug
Intervention Name(s)
Rectalgan Mousse
Intervention Description
for 4 weeks
Primary Outcome Measure Information:
Title
time for the disappearance of pain
Description
time for the disappearance of pain in course of treatment
Time Frame
1 month
Secondary Outcome Measure Information:
Title
time for the disappearance of bleeding
Description
time for the disappearance of bleeding in course of treatment
Time Frame
1 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects With Acute Anal Fissure Collaborative patients able to understand and want; Exclusion Criteria: Pregnancy
Facility Information:
Facility Name
Department of General Surgery "Paride Stefanini", University of Rome "La Sapienza"
City
Rome
State/Province
RM
ZIP/Postal Code
00161
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
12135106
Citation
Kim DW, Chi YS, Son KH, Chang HW, Kim JS, Kang SS, Kim HP. Effects of sophoraflavanone G, a prenylated flavonoid from Sophora flavescens, on cyclooxygenase-2 and in vivo inflammatory response. Arch Pharm Res. 2002 Jun;25(3):329-35. doi: 10.1007/BF02976635.
Results Reference
background
PubMed Identifier
11922398
Citation
Basile M, Gidaro S, Pacella M, Biffignandi PM, Gidaro GS. Parenteral troxerutin and carbazochrome combination in the treatment of post-hemorrhoidectomy status: a randomized, double-blind, placebo-controlled, phase IV study. Curr Med Res Opin. 2001;17(4):256-61.
Results Reference
background
PubMed Identifier
12188628
Citation
Mullen W, McGinn J, Lean ME, MacLean MR, Gardner P, Duthie GG, Yokota T, Crozier A. Ellagitannins, flavonoids, and other phenolics in red raspberries and their contribution to antioxidant capacity and vasorelaxation properties. J Agric Food Chem. 2002 Aug 28;50(18):5191-6. doi: 10.1021/jf020140n.
Results Reference
background
PubMed Identifier
12025911
Citation
Jantet G. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids. Angiology. 2002 May-Jun;53(3):245-56. doi: 10.1177/000331970205300301.
Results Reference
background
PubMed Identifier
10931020
Citation
Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids. Br J Surg. 2000 Jul;87(7):868-72. doi: 10.1046/j.1365-2168.2000.01448.x.
Results Reference
background
PubMed Identifier
29844250
Citation
Chiaretti M, Fegatelli DA, Ceccarelli G, Carru GA, Pappalardo G, Chiaretti AI. Comparison of Flavonoids and Centella asiatica for the treatment of chronic anal fissure. A randomized clinical trial. Ann Ital Chir. 2018;89:330-336.
Results Reference
result

Learn more about this trial

Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments

We'll reach out to this number within 24 hrs